CI
SRPT icon

Capital International’s Sarepta Therapeutics SRPT Stock Holding History

Capital International’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,458
Closed -$1.18M – 157
2025
Q1 		$1.18M Buy
18,458
+28
+0.2% +$2.95K 0.05% 143
2024
Q4 		$2.24M Buy
18,430
+4,357
+31% +$534K 0.09% 132
2024
Q3 		$1.76M Buy
+14,073
New +$1.95M 0.08% 136
2021
Q1 		– Sell
-1,265
Closed -$216K – 165
2020
Q4 		$216K Buy
+1,265
New +$187K 0.01% 159
2020
Q2 		– Sell
-400
Closed -$39K – 185
2020
Q1 		$39K Buy
+400
New +$45.7K ﹤0.01% 175

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Capital International's SRPT Position: Q2 2025 in Review

Capital International sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 18,458 shares — an estimated $1.18M sold.

Capital International first reported a position in SRPT in Q1 2020 and held it in 5 quarters. The position peaked at $2.24M in Q4 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Capital International reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Capital International sold 18,458 Sarepta Therapeutics shares in Q2 2025, an estimated $1.18M.
  • Capital International first reported a position in Sarepta Therapeutics in Q1 2020 and held it in 5 quarters.
  • Capital International's Sarepta Therapeutics position peaked at $2.24M in Q4 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Capital International's 13F filing for Q2 2025, filed 13 Aug 2025.